Genmab — Oktober 2018
-
that trial now seems fully recruited by the way, completion date delayed by a year though https://clinicaltrials.gov/ct2/history/NCT02432235?A=14&B=16&C=merged
-
#rolferren
-
JNJ-64407564 GPRC5D x CD3 for RMM seems to be enrolling well, with all centers recrtuing they are upping the # participants from 60 to 87 https://clinicaltrials.gov/ct2/show/NCT03399799?term=JNJ-64407564&rank=1
-
new Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia https://clinicaltrials.gov/ct2/show/NCT03679624?term=NCT03679624&rank=1
-
Der har tidligere været en del snak herinde om Tecentriq. De skuffede i München i dag i et brystkræft forsøg i kombi med kemo (Abraxane). Er det relevant for Gen?
-
Der har været en del snak omkring dead money og Genmabs pipeline, som jeg ikke helt forstår. De viser på hjemmesiden, omkring 20 igangværende fase 1-3 projekter samt 20 preclinical trials. (Er de forskellige kombinations forsøg, der omtales herinde jævnligt med Dara inkluderet i deres liste over forsøg?). Som jeg forstår det, er stort set intet af dette prisat i aktien (udover Dara). Så sml med andre Biotek, må Genmab da være temmeligt lavt prissat
-
God morgen.
-
@livermore : hvorfor er dette skidt nyt for Gen ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind